{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-022398","form_type":"8-K","ticker":"PMI","cik":"0002030617","company_name":"Picard Medical, Inc.","filed_at":"2026-07-02T12:15:19+00:00","discovered_at":"2026-07-02T12:20:00.481061+00:00","generated_at":"2026-07-02T12:20:11.968697+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Picard Medical reports 85% YoY revenue growth, gross margin improvement to 28% in pre-annual meeting presentation","bullets":["Revenue increased 85% YoY; US revenue up 116%; gross margin improved to 28% from year-end 2025.","Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.","Annual meeting on July 17, 2026; proposals include director elections, capital structure amendments, auditor ratification, exec comp advisory vote.","Interim CEO Richard Fang highlights business progress despite recent leadership changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-022398","json":"https://secwatch.observer/filing/0001437749-26-022398.json","markdown":"https://secwatch.observer/filing/0001437749-26-022398.md","text":"https://secwatch.observer/filing/0001437749-26-022398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/0001437749-26-022398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/pmi20251008_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T12:20:11.968697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}